TNGX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TN

Mkt Cap

$3.72B

Volume

3.13M

Next Earnings

November 3rd

Loading chart

TN

TNGXTango Therapeutics, Inc.

TNGX

Pay with—

Available Balance0.00

TN

Mkt Cap

$3.83B

Volume

3.13M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026.GlobeNewswire Inc. · Oct 16, 2026

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?Tango Therapeutics (TNGX) stock has declined 6.2% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a wider-than-expected loss of 37 cents per share due to higher operating expenses, with R&D expenses up 13% and G&A expenses nearly doubling. Collaboration revenues dropped to zero from $3.2 million year-over-year following the conclusion of its Gilead partnership. Analyst estimates have shifted downward by 10.16% in the past month, and the stock carries a Zacks Rank #3 (Hold) with poor VGM scores across growth, momentum, and value metrics.Zacks Investment Research · Sep 10, 2026

Tango Releases Controlling the Sequence: The 2026 Retail Real Estate Portfolio Execution IndexA new retail real estate portfolio execution index reveals that nearly all large retailers (97.6%) experience downstream problems from lease management decisions. The report finds that retailers manage roughly one major real estate project per week, but only 17% receive automated alerts for lease deadlines. Retailers using integrated third-party systems report significantly higher satisfaction (47%) compared to those using disconnected systems (19%), highlighting the competitive advantage of portfolio-level visibility and coordination.GlobeNewswire Inc. · Aug 25, 2026

Tango Therapeutics Announces Executive Chair TransitionDr. Barbara Weber, Executive Chairman of Tango Therapeutics (NASDAQ: TNGX), is stepping down to pursue other interests. The clinical-stage biotechnology company, which focuses on precision cancer medicines using synthetic lethality principles, expressed gratitude for Weber's leadership and vision while affirming confidence in the company's future direction under President Dr. Malte Peters.GlobeNewswire Inc. · Aug 6, 2026

Tango Therapeutics Announces Pricing of $600 Million Upsized Public OfferingTango Therapeutics priced an underwritten offering of 18.2 million shares at $30.00 per share and pre-funded warrants, expected to raise approximately $600 million in gross proceeds. The offering is expected to close on June 11, 2026, with J.P. Morgan, Leerink Partners, Cantor, and Stifel serving as joint bookrunning managers.GlobeNewswire Inc. · Jun 10, 2026

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%RTW Investments purchased 16,010,524 shares of Erasca for approximately $189.23 million in Q1 2026, with the position's value rising to $261.42 million by quarter-end. The clinical-stage biotech company, which develops oral inhibitors targeting the RAS/MAPK pathway for cancer treatment, has seen its stock surge 800% over the past year. The investment reflects confidence in Erasca's lead program ERAS-0015, which showed encouraging early data in KRAS-driven cancers, and the company's strong cash position of $408.5 million expected to fund operations into late 2028.The Motley Fool · May 30, 2026

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million MoreRTW Investments, a biotech-focused fund, purchased 11.8 million shares of Tango Therapeutics for approximately $164.37 million in Q1 2026, increasing its stake to roughly 3% of AUM. The purchase comes as TNGX stock has surged 840% over the past year. The investment reflects confidence in Tango's lead candidate vopimetostat and upcoming clinical data for MTAP-deleted cancers, with the company well-funded through 2028.The Motley Fool · May 30, 2026

The Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyInstitutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.GlobeNewswire Inc. · Mar 19, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Tango Therapeutics announced that its Compensation Committee granted a new employee 367,500 non-qualified stock options at an exercise price of $11.94 per share and 60,000 restricted stock units (RSUs) under the company's 2023 Inducement Plan. The options vest 25% after one year with monthly vesting thereafter, while RSUs vest in three tranches over three years, contingent on continued employment.GlobeNewswire Inc. · Mar 6, 2026

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC FilingBoxer Capital Management disclosed a $9.5 million purchase of 1.1 million shares of Tango Therapeutics (TNGX), increasing its stake to 21.09% of the fund's assets. The clinical-stage biotech company, which develops targeted cancer therapies through partnerships including one with Gilead Sciences, has seen its stock surge 426.7% over the past year.The Motley Fool · Mar 4, 2026

to start trading

TN

TNGXTango Therapeutics, Inc.

TNGX

Pay with—

Available Balance0.00

Your PositionYou don't own any TNGX yet.

Related Tickers

Earnings